MEF2C-AS2

Across TCGA pan-cancer cohorts, MEF2C-AS2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of MEF2C-AS2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where MEF2C-AS2 RNA is repressed in tumor relative to normal tissue. In most cancer types MEF2C-AS2 is over-expressed in tumor, although a few such as LUAD and KICH show the opposite, repressed pattern.

LUAD, KICH, and KIRC are the cancer types where MEF2C-AS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MEF2C-AS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−0.435	<.001	8	view →
KICH	All	II,III,IV	−0.090	.002	7	view →
KIRC	All	All	+0.064	.001	7	view →
BRCA	All	II,III,IV	−0.098	<.001	6	view →
COAD	All	IV	−0.095	.017	4	view →
HNSC	Male	III,IV	−0.181	.034	3	view →
LUSC	Male	All	−0.101	<.001	2	view →
THCA	All	II,III,IV	−0.078	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

MEF2C-AS2–LUAD

Open the LUAD breakdown →